Production of dengue 2 envelope domain III in plant using CPMV - based vector system

Marques, Lívia Érika Carlos; Silva, Bruno Bezerra da; Magalhães, Ilana Carneiro Lisboa; Mendes, Márcia Maria Marques; Almeida, Lia Magalhães de; Guedes, Maria Izabel Florindo

doi:10.1186/1753-6561-8-s4-p80

Cited by 4 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dengue DIII domain of the E protein (dEDIII) is considered as a primary target for vaccine development due to its potential to activate a neutralizing antibody responses ( Leng et al., 2009 ; Chen et al., 2013 ). dEDIII and the premembrane protein (prM) have been successfully expressed in cowpea, lettuce chloroplasts, N. benthamiana and tobacco chloroplasts ( Martínez et al., 2010 ; Kanagarajan et al, 2012 ; Carlos Marques et al., 2014 ; Gottschamel et al., 2016 ; van Eerde et al., 2019 ). For example, dEDIII was expressed in N. tabacum by stable nuclear transformation ( Kim et al, 2015 ), chloroplast transformation ( Gottschamel et al., 2016 ), or transient expression in N. benthamiana , with the latter approach leading to higher production levels ( Chen et al., 2013 ; Kim et al., 2015 ; Gottschamel et al., 2016 ).…”

Section: Plant-made Vaccines Against Viral Diseases In Humansmentioning

confidence: 99%

Plant-made vaccines against viral diseases in humans and farm animals

Eerde

Rimstad

et al. 2023

Front. Plant Sci.

View full text Add to dashboard Cite

Plants provide not only food and feed, but also herbal medicines and various raw materials for industry. Moreover, plants can be green factories producing high value bioproducts such as biopharmaceuticals and vaccines. Advantages of plant-based production platforms include easy scale-up, cost effectiveness, and high safety as plants are not hosts for human and animal pathogens. Plant cells perform many post-translational modifications that are present in humans and animals and can be essential for biological activity of produced recombinant proteins. Stimulated by progress in plant transformation technologies, substantial efforts have been made in both the public and the private sectors to develop plant-based vaccine production platforms. Recent promising examples include plant-made vaccines against COVID-19 and Ebola. The COVIFENZ® COVID-19 vaccine produced in Nicotiana benthamiana has been approved in Canada, and several plant-made influenza vaccines have undergone clinical trials. In this review, we discuss the status of vaccine production in plants and the state of the art in downstream processing according to good manufacturing practice (GMP). We discuss different production approaches, including stable transgenic plants and transient expression technologies, and review selected applications in the area of human and veterinary vaccines. We also highlight specific challenges associated with viral vaccine production for different target organisms, including lower vertebrates (e.g., farmed fish), and discuss future perspectives for the field.

show abstract

Section: Plant-made Vaccines Against Viral Diseases In Humansmentioning

confidence: 99%

Plant-made vaccines against viral diseases in humans and farm animals

Eerde

Rimstad

et al. 2023

Front. Plant Sci.

View full text Add to dashboard Cite

show abstract

Plant Molecular Farming for Vaccine Development

Okay

2024

Concepts and Strategies in Plant Sciences

View full text Add to dashboard Cite

Plant-Derived Recombinant Vaccines against Zoonotic Viruses

Zahmanova

Takova

Valkova

et al. 2022

Life

View full text Add to dashboard Cite

Emerging and re-emerging zoonotic diseases cause serious illness with billions of cases, and millions of deaths. The most effective way to restrict the spread of zoonotic viruses among humans and animals and prevent disease is vaccination. Recombinant proteins produced in plants offer an alternative approach for the development of safe, effective, inexpensive candidate vaccines. Current strategies are focused on the production of highly immunogenic structural proteins, which mimic the organizations of the native virion but lack the viral genetic material. These include chimeric viral peptides, subunit virus proteins, and virus-like particles (VLPs). The latter, with their ability to self-assemble and thus resemble the form of virus particles, are gaining traction among plant-based candidate vaccines against many infectious diseases. In this review, we summarized the main zoonotic diseases and followed the progress in using plant expression systems for the production of recombinant proteins and VLPs used in the development of plant-based vaccines against zoonotic viruses.

show abstract

Production of dengue 2 envelope domain III in plant using CPMV - based vector system

Cited by 4 publications

References 2 publications

Plant-made vaccines against viral diseases in humans and farm animals

Plant-made vaccines against viral diseases in humans and farm animals

Plant Molecular Farming for Vaccine Development

Plant-Derived Recombinant Vaccines against Zoonotic Viruses

Contact Info

Product

Resources

About